Flurala solution adapting to different water qualities and preparation method of flurala solution
By using a composite solvent system of solubilizer-cosolvent-defoamer and stabilizer, the stability and viscosity problems of fluranar solution in different water qualities were solved, achieving stable dissolution in different water qualities and application in low-temperature environments, reducing drug loss and foam generation.
Patent Information
- Application Number
- CN202411277556.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-08
AI Technical Summary
Existing fluranarine solutions are unstable in different water qualities, easily forming precipitates or degrading. They also have excessively high viscosity and generate a large amount of foam when stirred, leading to drug loss and inconvenience in use.
A Freranar solution was prepared by using a composite solvent system of solubilizer-cosolvent-defoamer, including polysorbate 80, diethylene glycol monoethyl ether and propylene glycol, with the addition of stabilizer α-tocopherol acetate or thioglycerol, and by homogenization and stirring.
It achieves stable dissolution of fluranar sodium solution in different water qualities, reduces viscosity, avoids foaming, improves production efficiency, adapts to different water quality application ranges, and ensures drug stability and flowability.
Smart Images

Figure BDA0005040681150000121 
Figure BDA0005040681150000131 
Figure BDA0005040681150000141
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of new veterinary drug preparations, and in particular to a flurellana solution suitable for different water qualities and a preparation method thereof. Background Art
[0002] Flurellana is a non-competitive antagonist of γ-aminobutyric acid receptor (GABA). It is a new type of highly effective insecticide and acaricide. Its molecules can block the ligand-gated chloride ion channels of GABA receptors, stimulate abnormal excitement of the nervous system, and ultimately lead to paralysis and death of target insects. At present, Flurellana is mainly used for the prevention and treatment of fleas and ticks in pet dogs and cats, red mites in poultry and other parasites. Combining the pharmacological effects of Flurellana and the drug use needs of modern efficient breeding models, Flurellana can be developed into an oral solution preparation for drinking water and applied in veterinary clinics.
[0003] However, when developing flurana into a solution, there are the following technical difficulties: (1) Flurana is insoluble in water, and a certain amount of cosolvent or solubilizer needs to be added to improve the solubility of flurana in water, so that the flurana solution can be diluted with water in any proportion, and will not precipitate or become turbid after being placed for a long time; (2) Flurana is sensitive to different water quality and is easily affected by metal ions in water to form precipitation. In addition, after dilution with drinking water containing hypochlorite, it is very easy to produce degradation reactions, resulting in inactivation of drug efficacy; (3) Flurana solution preparations contain a large amount of surfactants and have the problem of high viscosity. During production or use, long-term and vigorous stirring is required to ensure uniform mixing of the drugs. However, the above stirring operation easily causes the surfactant to produce a large amount of foam, affecting the subsequent packaging and use of the product. In addition, due to the high viscosity of the drug solution, there is a lot of residue in the production equipment or container during packaging or use, resulting in drug loss.
[0004] Invention patent CN201480068585.9 "Isoxazoline composition and its use in preventing or treating parasitic infestation in animals" proposes that flurellan can be used to prevent or treat parasitic infestation in animals, and its prescription composition is diethylene glycol monoethyl ether and polysorbate surfactant, and the amount of the two is less than 50%:50% (w / w). However, no stabilizer is introduced into its formula, which will cause the prepared flurellan solution to be unstable when diluted in drinking water containing hypochlorite, and it is very easy to degrade and inactivate.
[0005] Invention patent CN201910734505.3 "Isoxazoline composition and its use in preventing or treating parasitic infestations in animals" proposes that the use of α-tocopherol can prevent the degradation and inactivation of flurellana solution in drinking water containing hypochlorite, and its specific composition is: 0.95% flurellana, 8.2% α-tocopherol, 68.1% Tween 80, 22.7% diethylene glycol monoethyl ether. Although the above patent introduces α-tocopherol to solve the stability problem of flurellana when diluted in drinking water containing hypochlorite, the samples produced under the above formula still have the problem of high viscosity. It takes a long time and vigorous stirring in the production or use process to ensure that the drugs are mixed evenly, and a large amount of liquid medicine will remain in the production equipment or the sub-packaging container when it is sub-packed or poured out for use, resulting in drug loss. Moreover, it is worth noting that α-tocopherol itself is also very easy to be degraded and inactivated during the storage of the product. According to the quality standard of the flurellana solution disclosed by Intervet International Ltd., the content range of α-tocopherol is: 51.5mg to 90.2mg per 1mL, which means that the content of α-tocopherol can be reduced by nearly 50% during the validity period. In addition, the flurellana solution prepared in this patent needs to be added to the product and drinking water at the same time when it is used, so as to avoid the generation of a large amount of foam during the dilution process and affect the use.
[0006] The invention patent CN202111631718.7 "A Flurellan Insecticide, Its Preparation Method and Application" introduces a stabilizing system of cosolvents and composite diluents, which can ensure that Flurellan is not destroyed by water containing hypochlorite, and can significantly reduce the viscosity of the Flurellan solution. Its formula consists of: 1g Flurellan, 60g Tween 80, 10mL dimethylacetamide, 10g soybean oil, and anhydrous ethanol to 100mL. It mainly adopts anhydrous ethanol-Tween-80-soybean oil system, which can ensure that Flurellan is not destroyed by water containing hypochlorous acid and acts as a stabilizer. However, when the patent is diluted with drinking water during the production process, a large amount of foam will still be generated, which affects the packaging of the product and the drinking water of poultry and livestock. Summary of the invention
[0007] The main purpose of the present invention is to provide a flurellan solution adapted to different water qualities and a preparation method thereof, aiming to improve the technical problems that the existing flurellan solution is sensitive to different water qualities, is prone to precipitation or degradation reaction resulting in inactivation of drug efficacy, and that the existing flurellan solution preparation contains a large amount of surfactant resulting in excessive viscosity, and is prone to generate a large amount of foam during stirring, which is prone to remain in production equipment or containers, resulting in drug loss.
[0008] To achieve the above object, the present invention provides a flurana solution adaptable to different water qualities, comprising the following raw materials: flurana, a composite solvent and a stabilizer, wherein the composite solvent comprises a solubilizer, a co-solvent and a defoaming agent.
[0009] Preferably, based on the volume of 1 L of the flurana solution, the content of the flurana is 5 to 50 g / L, the content of the stabilizer is 1 to 40 g / L, and the remainder is the composite solvent.
[0010] Preferably, the stabilizer is at least one of α-tocopherol acetate or thioglycerol.
[0011] Preferably, the solubilizer is at least one of polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80; the cosolvent is at least one of diethylene glycol monoethyl ether or N-methylpyrrolidone; and the defoamer is at least one of propylene glycol or polypropylene glycol.
[0012] Preferably, the mass of the solubilizing agent: the volume of the co-solvent: and the mass of the defoaming agent = (50-60): (10-20): (5-10).
[0013] Preferably, the following raw materials are included: 10 g of flurellana, 40 g of stabilizer, 600 g of solubilizer, 100 g of defoamer, and the co-solvent is added to make up to 1 L;
[0014] The solubilizer is polysorbate 80; the defoamer is propylene glycol; the stabilizer is α-tocopherol acetate or thioglycerol; and the cosolvent is diethylene glycol monoethyl ether.
[0015] In addition, the present invention also proposes a method for preparing a flurellana solution adapted to different water qualities as described in any one of the above items, comprising the following preparation steps:
[0016] According to the proportion, the flurana, the cosolvent and the defoamer are stirred evenly; after homogenization, the stabilizer is added and stirred evenly; finally, the solubilizer is added and stirred evenly, so as to obtain the flurana solution adapted to different water qualities.
[0017] Preferably, the temperature in the homogenization and stirring steps is 18°C to 35°C; the homogenization power during the homogenization is 20 to 100 Hz, and the homogenization time is 10 to 30 min; the stirring speed in the stirring step is 20 to 100 rpm, and the stirring time is 10 to 30 min.
[0018] Preferably, after adding the solubilizing agent and stirring evenly, the solution is filtered to obtain the flurellana solution adapted to different water qualities, and the pore size of the filter during the filtering process is ≤0.45 μm.
[0019] Preferably, the viscosity of the flurellana solution is 5 to 30 mPa·s.
[0020] Preferably, the fluororana solution can withstand low temperature environments and is not prone to freezing or solidification under low temperature conditions.
[0021] Compared with the prior art, the fluororana solution adapted to different water qualities and the preparation method thereof of the present invention have the following beneficial effects:
[0022] 1. The flurellana solution of the present invention adopts a composite solvent system consisting of a solubilizer, a cosolvent, and a defoamer, preferably a composite of polysorbate 80-diethylene glycol monoethyl ether-propylene glycol, and α-tocopherol acetate or thioglycerol is used as a stabilizer, so that the flurellana solution can be completely dissolved in standard hard water and water containing hypochlorite in any proportion, and no precipitation or turbidity occurs after long-term storage. The drug can also be prevented from being degraded and inactivated by damage by metal ions or hypochlorite in water, which greatly broadens the application scope of the flurellana solution in aquaculture clinics.
[0023] 2. The diethylene glycol monoethyl ether-propylene glycol combination used in the flurellana solution of the present invention can significantly improve the viscosity of solubilizers such as polysorbate 80, significantly reduce the viscosity of the flurellana solution product, and its viscosity is not affected by temperature, thereby avoiding a large amount of retention in the container and reducing the loss of the drug solution.
[0024] 3. Propylene glycol is added to the flurellana solution of the present invention as a defoaming agent, which can eliminate the foam generated by surfactants such as polysorbate 80 during high-speed and long-term stirring, thereby facilitating packaging during industrial production and use in aquaculture clinics.
[0025] 4. The alpha-tocopherol acetate or thioglycerol with more stable properties is used as a stabilizer in the flurellana solution of the present invention. During the storage of the product during its shelf life, the content of the alpha-tocopherol acetate or thioglycerol is not easy to degrade and become ineffective, which is conducive to ensuring the stability of product quality.
[0026] 5. The flurellana solution prepared by the present invention has good tolerance to low temperature environment and will not freeze or solidify in low temperature environment, which is convenient for use in clinical breeding.
[0027] 6. The flurellana solution of the present invention adopts a homogenization-stirring mixing production process at room temperature, which greatly shortens the dissolution time of the drug in the solvent and significantly improves the production efficiency.
[0028] 7. The flurellana solution of the present invention has stable properties, a simple preparation method, and various raw and auxiliary materials are easily available, and the production cost is low, and is suitable for large-scale industrial production. DETAILED DESCRIPTION
[0029] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0030] In addition, the technical solutions between the various embodiments can be combined with each other, but it must be based on the fact that ordinary technicians in the field can implement it. When the combination of technical solutions is contradictory or cannot be implemented, it should be deemed that such combination of technical solutions does not exist and is not within the scope of protection required by the present invention.
[0031] A flurella solution adapted to different water qualities comprises the following raw materials: flurella, a composite solvent and a stabilizer, wherein the composite solvent comprises a solubilizer, a co-solvent and a defoaming agent.
[0032] The flurellana solution of this scheme introduces a composite solvent system of solubilizer-cosolvent-defoaming agent, so that the flurellana solution is not easy to generate a large amount of foam during production or use, and has low viscosity, good fluidity, and is easy to mix and dilute with water, and can also avoid the residue of the drug solution in the container, which is convenient for the subpackaging and use of the product. The flurellana solution finally prepared can be completely dissolved in water in any proportion, and the diluted solution is not easy to precipitate or become turbid after being left for a long time, and can also tolerate different water qualities. After being dissolved in different water qualities (such as hard water and drinking water containing hypochlorite), the drug can maintain good stability and is not easy to degrade and inactivate, which greatly broadens the application scope of the flurellana solution in aquaculture clinics.
[0033] In addition, due to the introduction of the composite solvent system of solubilizer-cosolvent-defoaming agent, the obtained flurellan solution is not easy to solidify under low temperature conditions and has good low temperature tolerance, which solves the problem of conventional oral solutions freezing and solidifying in winter and affecting their use.
[0034] Furthermore, based on the volume of the flurana solution being 1 L, the content of the flurana is 5 to 50 g / L, the content of the stabilizer is 1 to 40 g / L, and the remainder is the composite solvent.
[0035] The amount of each raw material in the flurellana solution is limited to the above range, so that the prepared flurellana solution has better performance and appropriate viscosity, and avoids the residue of the drug solution in the container.
[0036] Furthermore, the stabilizer is at least one of α-tocopherol acetate or thioglycerol.
[0037] Due to the complex sources of drinking water for aquaculture clinics, an appropriate amount of sodium hypochlorite is usually added to disinfect drinking water in actual aquaculture production, but flurellana is unstable in drinking water containing hypochlorite and will be degraded and inactivated. In order to solve this problem, α-tocopherol acetate or thioglycerol is added to the formula as a stabilizer. Unlike the traditional stabilizer α-tocopherol, its stability is poor and it is very easy to be oxidized and degraded during storage. During the storage process within the validity period of the flurellana solution, the content can drop by nearly 50%. Compared with α-tocopherol, the α-tocopherol acetate and thioglycerol used in this scheme are more stable, and can effectively protect flurellana from degradation and failure in drinking water containing hypochlorite. During the storage process within the validity period of the flurellana solution, the amount of its content decrease is much lower than that of α-tocopherol, which is more conducive to ensuring the formulation stability of the flurellana solution and its stability in a solution containing hypochlorite.
[0038] Furthermore, the solubilizer is at least one of polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80; the cosolvent is at least one of diethylene glycol monoethyl ether or N-methylpyrrolidone; and the defoamer is at least one of propylene glycol or polypropylene glycol.
[0039] In the composition of the flurellana solution, the solubilizer, co-solvent and defoamer can be made of the above-mentioned raw materials, which can significantly improve the solubility and stability of flurellana in different waters.
[0040] Among them, polysorbate 80 is a more preferred raw material. The small molecule micelles formed by polysorbate 80 in water can wrap the flurellana molecules therein, which can not only significantly improve the solubility of flurellana in water, but also avoid the combination of flurellana molecules with metal ions in water, thereby improving the stability of the drug in water. However, flurellana API is difficult to completely dissolve in polysorbate 80, and a white turbid liquid will be formed after the two are mixed, and a solution preparation cannot be directly prepared, and the drugability is poor. Therefore, a cosolvent needs to be added, and the cosolvent is preferably diethylene glycol monoethyl ether. It should be noted that although flurellana can be directly dissolved in diethylene glycol monoethyl ether to prepare a solution preparation, a white precipitate will be precipitated immediately after the solution preparation is diluted with water, and it is easy to block the drinking water pipeline. Therefore, it is necessary to introduce polysorbate, and flurellana can be completely dissolved in a polysorbate 80-diethylene glycol monoethyl ether composite solvent to form a clear solution, and the obtained flurellana solution can be completely dissolved in different waters in any proportion, and it is not easy to precipitate or become turbid after being placed for a long time.
[0041] However, in actual production, due to the large amount of surfactant-polysorbate 80 in the flurana solution, the flurana solution is very likely to generate a large amount of foam during the stirring process, which will affect the packaging of the product during the production process and will also affect the drinking water of poultry and livestock during clinical use in breeding. In order to solve the above problems, a defoamer that can inhibit the generation of foam is added to the formula. Unlike traditional fat-soluble defoamers (such as silicone oil, sodium oleate and sodium octanoate and their mixtures), which have the disadvantage of poor solubility in water, this scheme uses propylene glycol or polypropylene glycol as a defoamer, which can be completely dissolved in water. The defoamer is preferably propylene glycol, which can not only effectively eliminate the foam generated by polysorbate 80 in production or in breeding clinics; it can also improve the solubility of flurana to a certain extent; at the same time, when diethylene glycol monoethyl ether and propylene glycol are used in combination, the viscosity of polysorbate 80 can also be improved, thereby making the obtained flurana solution have lower viscosity and better fluidity.
[0042] Furthermore, the mass of the solubilizing agent: the volume of the cosolvent: the mass of the defoaming agent = (50-60): (10-20): (5-10). In actual production, the amount of each component in the composite solvent system is limited to the above range, wherein the amount of the solubilizing agent-polysorbate is relatively large, and the amount of other components is relatively small. Within the above dosage range, the obtained flurellana solution has good solubility, is not easy to produce foam, and has lower viscosity. The solubilizing agent, cosolvent and defoaming agent are polysorbate 80, diethylene glycol monoethyl ether and propylene glycol, respectively. Among them, polysorbate 80 and propylene glycol are relatively viscous liquids. In actual production, samples of corresponding mass are weighed. Therefore, m in the solubilizing agent and defoaming agent refers to mass, while the cosolvent is mainly based on volume.
[0043] Furthermore, the flurellana solution adapted to different water qualities comprises the following raw materials: 10 g of flurellana, 40 g of stabilizer, 600 g of solubilizer, 100 g of defoamer, and the co-solvent is added to make up to 1 L;
[0044] The solubilizer is polysorbate 80; the defoamer is propylene glycol; the stabilizer is α-tocopherol acetate or thioglycerol; and the cosolvent is diethylene glycol monoethyl ether.
[0045] More preferably, the flurellana solution comprises 10 g of flurellana, 600 g of polysorbate 80, 100 g of propylene glycol, 40 g of α-tocopheryl acetate / thioglycerol, and diethylene glycol monoethyl ether to make up to 1 L. When the above raw materials and dosages are limited, the obtained flurellana solution has the best performance.
[0046] The present invention also provides a method for preparing a flurana solution adapted to different water qualities as described in any one of the above items, comprising the following preparation steps: stirring the flurana, the cosolvent and the defoamer evenly according to a ratio; adding a stabilizer after homogenization and stirring evenly; and finally adding a solubilizer and stirring evenly to obtain the flurana solution adapted to different water qualities.
[0047] The preparation steps of the flurellana solution adapted to different water qualities in this scheme include: adding the prescribed amount of flurellana, cosolvent, and defoamer to a stirring tank, homogenizing at room temperature, then adding the prescribed amount of stabilizer, stirring evenly at room temperature, and finally adding the prescribed amount of solubilizer, stirring evenly at room temperature; filtering the above liquid medicine through a filter element, packaging, and sealing for storage. The preparation process of the flurellana solution is simple and can be applied to large-scale industrial production.
[0048] In the preparation method of flurellana solution, the addition of materials is subject to certain order restrictions, and the order of addition is: flurellana, cosolvent, defoamer, then stabilizer, and finally solubilizer. This is mainly because flurellana is difficult to dissolve directly in stabilizers such as α-tocopherol acetate and thioglycerol and solubilizers such as polysorbate 80. Therefore, flurellana is first dispersed in cosolvents such as diethylene glycol monoethyl ether and defoamers such as propylene glycol, and then homogenized to make flurellana dissolve quickly, greatly shortening the dissolution time of the raw material and significantly improving production efficiency; after the drug is completely dissolved, the stabilizer is added to mix evenly. In order to avoid the generation of a large amount of foam by surfactants such as polysorbate 80 when stirring vigorously, it is added to the stirring tank at the end of the production process to reduce the stirring process and avoid the generation of foam.
[0049] Furthermore, the temperature in the homogenization and stirring steps is 18°C to 35°C; the homogenization power during the homogenization is 20 to 100 Hz, and the homogenization time is 10 to 30 min; the stirring speed in the stirring step is 20 to 100 rpm, and the stirring time is 10 to 30 min.
[0050] The preparation process of the flurellana solution is usually carried out directly at room temperature, and the temperature range can be 18° C. to 35° C. Within the above temperature range, stabilizers such as α-tocopherol acetate and thioglycerol can be kept stable during the production process, and no heating treatment is required, and the production process is simple.
[0051] In the homogenization process of the preparation method of flurellana solution, the homogenization power is 20 to 100 Hz and the homogenization time is 10 to 30 minutes. After the homogenization process, flurellana is quickly dissolved in solvents such as diethylene glycol monoethyl ether and propylene glycol. If conventional stirring and dissolving process is adopted, the stirring time needs to be more than 1 hour to completely dissolve the drug.
[0052] In the stirring process of the preparation of the flurellana solution, the stirring speed is 20 to 100 rpm and the stirring time is 10 to 30 minutes. Since solubilizers such as polysorbate 80 are very likely to generate a large amount of foam under high-speed and long-term stirring, the stirring speed and stirring time are controlled as much as possible within the above range.
[0053] Furthermore, after adding a solubilizing agent and stirring evenly, the solution is filtered to obtain the flurellana solution adapted to different water qualities, and the pore size of the filter during the filtering process is ≤0.45 μm.
[0054] The preparation process of the flurana solution also requires filtration treatment. The pore size of the filter element is 0.45μm. Since the particle size of most bacteria is in the range of 0.5 to 5μm, combined with the actual situation of the industrial production workshop, a filter element with a pore size of about 0.45μm can be selected for filtration. In addition to removing filterable microparticle impurities, it can also filter out bacteria in the solution to ensure the stability of product quality.
[0055] The material of the filter element is one of polytetrafluoroethylene, polypropylene or silicone rubber. This is mainly because the solvents used in the formulation of the flurana solution are all organic solvents. Therefore, a filter element made of a material that can tolerate organic solvents is required. Polytetrafluoroethylene, polypropylene or silicone rubber have good tolerance to organic solvents and will not affect the quality of the product. They can be used as materials for flurana solution filter elements.
[0056] Furthermore, the viscosity of the flurellana solution is 5 to 30 mPa·s. The viscosity of the flurellana solution obtained after being processed by the above raw materials and preparation method is significantly reduced, and its viscosity is not affected by temperature, thereby avoiding a large amount of retention in the container and avoiding the loss of the drug solution.
[0057] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.
[0058] Example 1
[0059] 10g of flurellana, 240mL of cosolvent (diethylene glycol monoethyl ether), and 100g of defoamer (propylene glycol) were added to a stirring tank, and homogenized at 50Hz for 10min at room temperature to completely dissolve the drug and form a clear solution. 40g of stabilizer (α-tocopherol acetate) was added, and stirred at 50rpm for 10min at room temperature. 600g of solubilizer (polysorbate 80) was added, and cosolvent (diethylene glycol monoethyl ether) was added to make up to 1L, and stirred at 50rpm for 10min at room temperature. The above-mentioned drug solution was filtered through a filter element made of polytetrafluoroethylene with a pore size of 0.45μm, and packaged to obtain the product.
[0060] Example 2—(Replacing the α-tocopherol acetate of Example 1 with thioglycerol)
[0061] 10g of flurellana, 240mL of cosolvent (diethylene glycol monoethyl ether), and 80g of defoamer (propylene glycol) were added to a stirring tank, and homogenized at 50Hz for 10min at room temperature to completely dissolve the drug to form a clear solution, 40g of stabilizer (thioglycerol) was added, and stirred at 50rpm for 10min at room temperature, 600g of solubilizer (polysorbate 80) was added, and cosolvent (diethylene glycol monoethyl ether) was added to 1L, and stirred at 50rpm for 10min at room temperature. The above-mentioned drug solution was filtered through a filter element made of polytetrafluoroethylene with a pore size of 0.45μm, and packaged to obtain the product.
[0062] Example 3
[0063] 15g of flurellana, 200mL of cosolvent (N-methylpyrrolidone), and 80g of defoamer (polypropylene glycol 400) were added to a stirring tank, and homogenized at 60Hz for 10min at room temperature to completely dissolve the drug and form a clear solution. 40g of stabilizer (α-tocopherol acetate) was added, and stirred at 70rpm for 15min at room temperature. 600g of solubilizer (polysorbate 80) and cosolvent (N-methylpyrrolidone) were added to 1L, and stirred at 40rpm for 20min at room temperature. The above-mentioned drug solution was filtered through a filter element made of polytetrafluoroethylene with a pore size of 0.45μm, and packaged to obtain the product.
[0064] Example 4
[0065] 20g of flurellana, 240mL of cosolvent (N-methylpyrrolidone), and 100g of defoamer (propylene glycol) were added to a stirring tank, and homogenized at 45Hz for 25min at room temperature to completely dissolve the drug and form a clear solution. 40g of stabilizer (thioglycerol) was added, and the mixture was stirred at 80rpm for 10min at room temperature. 620g of solubilizer (polysorbate 80) and cosolvent (N-methylpyrrolidone) were added to 1L, and the mixture was stirred at 40rpm for 10min at room temperature. The above-mentioned liquid medicine was filtered through a filter element made of polytetrafluoroethylene with a pore size of 0.45μm, and packaged to obtain the product.
[0066] Comparative Example 1—(Comparative Example 1 was not homogenized)
[0067] 10g of flurellana, 240mL of diethylene glycol monoethyl ether, and 100g of propylene glycol were added to a stirring tank and stirred at 50rpm at room temperature. It took 90min for the drug to completely dissolve and form a clear solution. 40g of α-tocopherol acetate was added and stirred at 50rpm for 10min at room temperature. 600g of polysorbate 80 and the remaining amount of N-methylpyrrolidone were added to 1L and stirred at 50rpm for 10min at room temperature. The above-mentioned drug solution was filtered through a filter element made of polytetrafluoroethylene with a pore size of 0.45μm and packaged to obtain the drug.
[0068] Comparative Example 2
[0069] The preparation steps and parameters in this comparative example are the same as those in Example 1, except that diethylene glycol monoethyl ether is replaced with polysorbate 80.
[0070] Comparative Example 3
[0071] The preparation steps and parameters in this comparative example are the same as those in Example 1, except that polysorbate 80 is replaced with diethylene glycol monoethyl ether. The obtained sample is a colorless clear solution.
[0072] Comparative Example 4
[0073] The preparation steps and parameters in this comparative example are the same as those in Example 1, except that α-tocopherol acetate is not added. The prepared sample is a light yellow clear solution.
[0074] Comparative Example 5
[0075] The preparation steps and parameters in this comparative example are the same as those in Example 1, except that propylene glycol is not added. The obtained sample is a light yellow clear solution.
[0076] Comparative Example 6
[0077] This comparative example adopts the first flurella solution formulation process in the prior art to prepare the flurella solution, comprising the following steps:
[0078] 10g of flurellana and 200mL of diethylene glycol monoethyl ether were added to a stirring tank and stirred at 50rpm. It took 30min for the drug to completely dissolve and form a clear solution. 85g of α-tocopherol was added and stirred at 50rpm for 10min. 680g of polysorbate 80 and the remaining amount of diethylene glycol monoethyl ether were added to 1L and stirred at 50rpm for 20min to mix evenly. The above-mentioned drug solution was filtered through a filter element made of polytetrafluoroethylene with a pore size of 0.45μm and packaged to obtain the product.
[0079] Comparative Example 7
[0080] This comparative example adopts the second flurana solution formulation process in the prior art to prepare the flurana solution, comprising the following steps:
[0081] 10 g of flurellana, 100 mL of dimethylacetamide, and 100 g of soybean oil were added to a stirring tank and stirred at 50 rpm. It took 60 min for the drug to completely dissolve and form a light yellow clear solution. 600 g of polysorbate 80 and 1 L of ethanol were added and stirred at 50 rpm for 20 min to mix evenly. Filtration was the same as in Example 1. The above-mentioned drug solution was filtered through a filter element made of polytetrafluoroethylene with a pore size of 0.45 μm and packaged to obtain the drug.
[0082] The fluororana solutions prepared in the above Examples 1-4 and Comparative Examples 1-7 were subjected to the following performance tests: Test 1: Evaluation of Appearance Properties
[0083] The properties of the samples in Examples 1-4 and Comparative Examples 1-7 were observed with the naked eye. According to the requirements of Appendix 0111 General Rules for Oral Solution Preparations of the "Chinese Pharmacopoeia of Veterinary Medicine" (2020 Edition), they should be clear solutions.
[0084] Table 1 Evaluation results of properties of the flurellana solution embodiments and comparative examples of the present invention
[0085] sample Sample properties Example 1 Light yellow clear solution Example 2 Light yellow clear solution Example 3 Light yellow clear solution Example 4 Light yellow clear solution Comparative Example 1 Light yellow clear solution Comparative Example 2 Yellow-white turbid solution Comparative Example 3 Colorless clear solution Comparative Example 4 Light yellow clear solution Comparative Example 5 Light yellow clear solution Comparative Example 6 Light yellow clear solution Comparative Example 7 Light yellow clear solution
[0086] From the observation results in Table 1 above, it can be seen that Examples 1 to 4 are all light yellow clear solutions; Comparative Examples 1, 4, 5, 6 and 7 are also light yellow clear solutions. However, in Comparative Example 2, due to the absence of the co-solvent diethylene glycol monoethyl ether, flurellanine cannot be completely dissolved, and the final sample is a yellow-white turbid solution. In Comparative Example 3, due to the absence of the solubilizer polysorbate 80, the sample is a colorless clear solution.
[0087] Test 2: Viscosity measurement
[0088] According to the provisions of Appendix 0633 Viscosity Determination Method of the "Chinese Pharmacopoeia of Veterinary Medicine" (2020 Edition), the viscosity values of each sample of Examples 1-4 and Comparative Examples 1-7 at room temperature (20°C), 4°C and -20°C were respectively measured.
[0089] Table 2 Viscosity evaluation results of the flurellana solution embodiments and comparative examples of the present invention
[0090]
[0091]
[0092] Note: The properties of Comparative Example 2 did not meet the requirements and were not evaluated. Comparative Example 6 solidified at -20°C and was not evaluated.
[0093] It can be seen from the test results in Table 2 above that under normal temperature conditions, the viscosity of the flurana solution of Examples 1 to 4 is significantly lower than that of Comparative Example 6, and there is no significant difference with Comparative Example 7. However, under low temperature conditions, the viscosity of Examples 1 to 4 does not change significantly, while the viscosity of Comparative Example 7 increases significantly. The viscosity of Comparative Examples 1, 3 and 4 is not significantly different from that of Examples 1 and 2, indicating that the diethylene glycol monoethyl ether and propylene glycol in the formula can significantly reduce the viscosity of the sample, making the fluidity of the flurana solution better, avoiding the residue of the drug solution in the container, and is also more conducive to the dispersion and dissolution of the drug solution in water.
[0094] Test 3: Low temperature tolerance test
[0095] The samples of Examples 1-4 and Comparative Examples 1-7 were placed at -20°C for 30 days, and the samples were observed on the 0th, 10th, 20th and 30th days to see if they were frozen or solidified.
[0096] Table 3 Evaluation results of low temperature tolerance of flurellana solution examples and comparative examples of the present invention
[0097] sample 0-day characteristics Properties after 10 days Properties after 20 days Properties after 30 days Example 1 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution Example 2 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution Example 3 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution Example 4 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution Comparative Example 1 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution Comparative Example 3 Colorless clear solution Colorless clear solution Colorless clear solution Colorless clear solution Comparative Example 4 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution Comparative Example 5 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution Comparative Example 6 Light yellow clear solution Turns into a gel Turns into a gel Turns into a gel Comparative Example 7 Light yellow clear solution Light yellow clear solution Light yellow clear solution Light yellow clear solution
[0098] Note: The properties of comparative example 2 did not meet the requirements and were not evaluated.
[0099] From the test results in Table 3 above, it can be seen that Comparative Example 6 is very easy to form a gel at -20°C, while the other samples can withstand the influence of low temperature conditions and no freezing or solidification is observed.
[0100] Test 4: Anti-foaming performance evaluation
[0101] (1) Evaluation of sample anti-foaming performance: 100 mL of each sample of Examples 1-4 and Comparative Examples 1-7 were taken and dispensed into glass test tubes with stoppers (the sample solution occupied one-third of the test tubes), and the samples were shaken vigorously for 2 minutes. The glass test tubes were then placed on a test tube rack to observe the foam generation and foam elimination in the samples.
[0102] (2) Evaluation of anti-foaming performance after dilution in water: Take 10 mL of each sample of Examples 1-4 and Comparative Examples 1-7, add them into 100 mL of purified water, stir the dilution vigorously and rapidly for 2 min using a glass rod, and observe the foam generation and foam elimination in the dilution.
[0103] Table 4 Evaluation results of anti-foaming performance of flurellana solution embodiments and comparative examples of the present invention
[0104]
[0105] Note: The properties of comparative example 2 did not meet the requirements and were not evaluated.
[0106] As can be seen from the test results in Table 4 above, since Comparative Example 3 does not contain solubilizing agent polysorbate 80, its sample solution and diluent will not produce foam. While Examples 1 to 4, Comparative Example 1 and Comparative Example 4 all contain a certain amount of propylene glycol, and their sample solutions and diluents will produce a small amount of foam after vigorous shaking or stirring, but the foam disappears quickly and does not affect the quality and use of the product. As for Comparative Examples 5, 6 and 7, since the formula does not contain defoaming agent, their sample solutions and diluents will produce a large amount of foam after vigorous shaking or stirring, and it is not easy to eliminate.
[0107] Test 5: Stability of dilutions in different waters
[0108] (1) Dilution stability in purified water: Take each sample of Examples 1-4 and Comparative Examples 1-7, dilute and dissolve them with purified water at a ratio of 1:10, 1:100 and 1:1000, place them at room temperature for 24 hours, and observe the properties of each sample dilution. The results are shown in Table 5.
[0109] (2) Standard hard water dilution stability: Take each sample of Examples 1-4 and Comparative Examples 1-7, dilute and dissolve them with standard hard water at a ratio of 1:10, 1:100 and 1:1000, place them at room temperature for 24 hours, and observe the properties of each sample dilution. The results are shown in Table 6.
[0110] (3) Dilution stability in 50 ppm sodium hypochlorite solution: Samples of Examples 1-4 and Comparative Examples 1-7 were diluted and dissolved with 50 ppm sodium hypochlorite solution at a ratio of 1:10, 1:100 and 1:1000, and placed at room temperature for 24 hours to observe the properties of the dilutions of each sample. The results are shown in Table 7.
[0111] Table 5 Evaluation results of dilution stability of flurellana solution in purified water in the embodiments and comparative examples of the present invention
[0112]
[0113]
[0114] Table 6 Evaluation results of dilution stability of the flurellana solution of the present invention and the comparative example in standard hard water
[0115]
[0116]
[0117] Table 7 Evaluation results of dilution stability of flurellana solution of the present invention and comparative examples in 50ppm sodium hypochlorite solution
[0118]
[0119]
[0120] Note: The prescription of comparative example 1 is consistent with that of example 1, so no evaluation is performed. The properties of comparative example 2 fail to meet the requirements, so no evaluation is performed.
[0121] It can be seen from the test results of Tables 5 to 7 that the flurellana solutions of Examples 1 to 4 were diluted and dissolved with purified water, standard hard water and 50ppm sodium hypochlorite solution at a ratio of 1:10, 1:100 and 1:1000, respectively, and placed at room temperature for 24 hours, and no precipitation or turbidity was observed, and they were still colorless clear solutions. The flurellana solution of Comparative Example 3 did not contain the solubilizing agent polysorbate 80, and it was diluted with purified water, standard hard water and 50ppm sodium hypochlorite solution at a ratio of 1:100 and 1:1000 to become a white turbid solution, and a large amount of drug precipitation was precipitated after standing. In addition, although Comparative Examples 5 and Comparative Examples 7 were diluted with purified water, standard hard water and 50ppm sodium hypochlorite solution at a ratio of 1:100 and 1:1000 to form colorless clear solutions, a small amount of precipitation was still present after being placed for 24 hours.
[0122] Experiment 6: Stability of drugs after dilution in different waters
[0123] After being placed at 0h and room temperature for 24h, the dilutions of each sample in the above test 5 were dissolved at a ratio of 1:100, and appropriately diluted with 90% acetonitrile solution, and then analyzed by liquid phase detection, and the drug content in each sample dilution was calculated. The results can be seen in Table 8.
[0124] Table 8 Evaluation results of drug stability of the flurellana solution embodiments and comparative examples of the present invention after dilution (1:100) in water of different water qualities
[0125]
[0126] Note: The properties of Comparative Example 2 did not meet the requirements and were not evaluated. The diluted solution of Comparative Example 3 was a turbid solution and could not meet the use requirements and was not evaluated.
[0127] From the test results in Table 8 above, it can be seen that after the flurellana solutions of Examples 1 to 4 were diluted in purified water, standard hard water and 50ppm sodium hypochlorite solution, the drugs were relatively stable and the drug content did not decrease significantly. However, the flurellana solution in Comparative Example 4 did not contain a stabilizer, and its stability in 50ppm sodium hypochlorite solution was poor. After being placed for 24 hours, the drug content decreased by 20.66%, and its stability in purified water and standard hard water was not as good as that of Examples 1 and 2. The flurellana solutions of Comparative Examples 5, 6 and 7 were also not as stable as those of Examples 1 and 2 in purified water, standard hard water and 50ppm sodium hypochlorite solution.
[0128] Experiment 7: Stability study of different samples
[0129] Each sample of Examples 1-4 and Comparative Examples 1-7 was placed under accelerated test conditions of (40±2)°C and (75±5)% relative humidity for 6 months, and samples were taken regularly to observe the appearance of each sample and to detect the drug content and key auxiliary material stabilizer content in the sample, and to investigate the stability of each sample under accelerated test conditions. The results can be seen in Table 9.
[0130] Table 9 Stability evaluation results of the flurellana solution embodiments and comparative examples of the present invention under accelerated test conditions
[0131]
[0132]
[0133] Note: The properties of comparative example 2 did not meet the requirements and were not evaluated.
[0134] As shown in the test result of Table 9, Example 1 and Example 3 adopt alpha-tocopherol acetate as stabilizer, and after being placed under accelerated test conditions for 6 months, drug content decreased by 1.48% and 1.58%, respectively, and alpha-tocopherol acetate decreased to 34.69mg / mL and 35.24mg / mL from 38.72mg / mL and 39.25mg / mL, respectively, and the drug content in the sample and the content of stabilizer are all relatively stable. Example 2 and Example 4 adopt thioglycerol as stabilizer, and after being placed under accelerated test conditions for 6 months, drug content decreased by 1.81% and 1.31%, respectively, and thioglycerol decreased to 33.78mg / mL and 33.85mg / mL from 38.56mg / mL and 39.54mg / mL, respectively, and the drug content in the sample and the content of stabilizer are all relatively stable.
[0135] The formula of Comparative Example 1 is consistent with that of Example 1, and its stability is basically the same. After being placed under accelerated test conditions for 6 months, the drug content of Comparative Example 3, Comparative Example 4 and Comparative Example 5 decreased by 5.80%, 9.79% and 5.21% respectively, and the stability is not as good as that of Example 1 and Example 2. Comparative Example 6 uses α-tocopherol as a stabilizer, and after being placed under accelerated test conditions for 6 months, the drug content only decreased by 4.86%, and α-tocopherol decreased from 83.67 mg / mL to 38.24 mg / mL, and the content of α-tocopherol decreased by 54.30%. After being placed under accelerated test conditions for 6 months, the drug content of Comparative Example 7 decreased by 4.08%, and the stability is not as good as that of Example 1 and Example 2.
[0136] In summary, the flurellana solution samples of Examples 1-4 provided by the present invention can be completely dissolved in purified water, standard hard water and water containing hypochlorite in any proportion, and the dilution stability in different water qualities is good, the drug is not easily degraded and inactivated, and can adapt to different water qualities in aquaculture clinics. At the same time, the prepared samples have good fluidity and can withstand low temperature environments, which can fully meet the drug use needs of aquaculture clinics.
[0137] The above embodiments are only preferred embodiments of the present invention, and are not intended to limit the patent scope of the present invention. The fluororana solution mentioned in the present invention is not limited to the above-mentioned ones, so the above embodiments cannot be regarded as limiting the protection scope of the present invention. All equivalent structural changes made by using the contents of the present invention specification under the inventive concept of the present invention, or direct / indirect application in other related technical fields are included in the patent protection scope of the present invention.
Claims
1. A flurellana solution adapted to different water qualities, characterized in that: The invention comprises the following raw materials: flurana, a composite solvent and a stabilizer; the composite solvent comprises a solubilizer, a co-solvent and a defoaming agent.
2. The fluororana solution adapted to different water qualities according to claim 1, characterized in that: Based on the volume of the flurana solution being 1 L, the content of the flurana is 5 to 50 g / L, the content of the stabilizer is 1 to 40 g / L, and the remainder is the composite solvent.
3. A fluororana solution adapted to different water qualities according to claim 1 or 2, characterized in that: The stabilizer is at least one of α-tocopherol acetate or thioglycerol.
4. A fluororana solution adapted to different water qualities according to claim 1 or 2, characterized in that: The solubilizer is at least one of polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80; the cosolvent is at least one of diethylene glycol monoethyl ether or N-methylpyrrolidone; and the defoamer is at least one of propylene glycol or polypropylene glycol.
5. A fluororana solution adapted to different water qualities according to claim 1 or 2, characterized in that: The mass of the solubilizing agent: the volume of the co-solvent: the mass of the defoaming agent = (50-60): (10-20): (5-10).
6. A fluororana solution adapted to different water qualities according to claim 1 or 2, characterized in that: The flurellana solution adapted to different water qualities comprises the following raw materials: 10 g of flurellana, 40 g of stabilizer, 600 g of solubilizer, 100 g of defoamer, and the cosolvent is added to make up to 1 L; The solubilizer is polysorbate 80; the defoamer is propylene glycol; the stabilizer is α-tocopherol acetate or thioglycerol; and the cosolvent is diethylene glycol monoethyl ether.
7. A method for preparing a flurellana solution adapted to different water qualities as claimed in any one of claims 2 to 6, characterized in that: The method comprises the following steps: mixing the flurana, the cosolvent and the defoamer evenly according to the proportion; adding a stabilizer after homogenization and mixing evenly; and finally adding a solubilizer and mixing evenly to obtain the flurana solution adapted to different water qualities.
8. The method for preparing a flurana solution adapted to different water qualities according to claim 7, characterized in that: The temperature in the homogenization and stirring steps is 18°C to 35°C; the homogenization power in the homogenization is 20 to 100 Hz, and the homogenization time is 10 to 30 minutes; the stirring speed in the stirring step is 20 to 100 rpm, and the stirring time is 10 to 30 minutes.
9. The method for preparing a flurana solution adapted to different water qualities according to claim 7, characterized in that: After adding the solubilizing agent and stirring evenly, the solution is filtered to obtain the flurellana solution adapted to different water qualities. The pore size of the filter during the filtering process is ≤0.45 μm.
10. The method for preparing a flurellana solution adapted to different water qualities according to claim 7, characterized in that: The viscosity of the flurellana solution is 5 to 30 mPa·s.
Citation Information
Cited By
A solution formulation of fluralaner and a method of preparing the same
CN123038017A
